Alison J Moskowitz

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Alison J Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    J Clin Oncol 31:456-60. 2013
  2. pmc Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Alison J Moskowitz
    Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
    Br J Haematol 146:158-63. 2009
  3. doi request reprint Novel agents in Hodgkin lymphoma
    Alison J Moskowitz
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Curr Oncol Rep 14:419-23. 2012
  4. pmc Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Alison J Moskowitz
    Lymphoma Service of the Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:4934-7. 2010
  5. pmc Controversies in the treatment of lymphoma with autologous transplantation
    Alison J Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 14:921-9. 2009
  6. doi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
  7. pmc Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve
    Matthew A Lunning
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 31:1922-7. 2013
  8. pmc Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Craig H Moskowitz
    Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:1665-70. 2012
  9. doi request reprint How I treat the peripheral T-cell lymphomas
    Alison J Moskowitz
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and
    Blood 123:2636-44. 2014
  10. ncbi request reprint Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long
    Alison J Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer J 18:445-9. 2012

Detail Information

Publications10

  1. pmc Phase II study of bendamustine in relapsed and refractory Hodgkin lymphoma
    Alison J Moskowitz
    Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
    J Clin Oncol 31:456-60. 2013
    ..Limited data exist regarding the activity of bendamustine in Hodgkin lymphoma (HL). This phase II study evaluated the efficacy of bendamustine in relapsed and refractory HL...
  2. pmc Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma
    Alison J Moskowitz
    Medical Oncology Hematology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, Box 8, New York, NY 10065, USA
    Br J Haematol 146:158-63. 2009
    ..Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months...
  3. doi request reprint Novel agents in Hodgkin lymphoma
    Alison J Moskowitz
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, 10065, USA
    Curr Oncol Rep 14:419-23. 2012
    ..Current challenges in HL research include identifying the most appropriate drug combinations of new and old drugs and identifying predictors of response to the new targeted agents...
  4. pmc Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
    Alison J Moskowitz
    Lymphoma Service of the Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 116:4934-7. 2010
    ..055). Studies evaluating novel STs, conditioning regimens, post-ASCT maintenance, or allogeneic stem cell transplantation are warranted for patients who fail to normalize pre-ASCT functional imaging...
  5. pmc Controversies in the treatment of lymphoma with autologous transplantation
    Alison J Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Oncologist 14:921-9. 2009
    ....
  6. doi request reprint High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging
    Craig H Moskowitz
    Division of Hematologic Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Br J Haematol 148:890-7. 2010
    ..61. Risk-adapted augmentation of salvage treatment in patients with HL is feasible and improves EFS in poorer-risk patients. Our data suggest that normalisation of FI pre-ASCT predicts outcome, and should be the goal of salvage treatment...
  7. pmc Strategies for relapsed peripheral T-cell lymphoma: the tail that wags the curve
    Matthew A Lunning
    Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 31:1922-7. 2013
    ..After two cycles, she achieved a partial response, and after four additional cycles, she maintained her response without further improvement. We discussed additional treatment options...
  8. pmc Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Craig H Moskowitz
    Lymphoma Disease Management Team, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Blood 119:1665-70. 2012
    ..6% for patients with a positive scan (P < .001). This prospective study provides evidence that the goal of SLT in patients with Hodgkin lymphoma should be a negative FDG-PET scan before HDT/ASCT...
  9. doi request reprint How I treat the peripheral T-cell lymphomas
    Alison J Moskowitz
    Lymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and
    Blood 123:2636-44. 2014
    ..As a result, over the next few years, we expect a significant shift in our management of these diseases with a move toward more individualized therapy leading to improved outcomes. ..
  10. ncbi request reprint Should patients with aggressive peripheral T-cell lymphoma all be treated the same?: no... well yes, ...but maybe not for long
    Alison J Moskowitz
    Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Cancer J 18:445-9. 2012
    ....